{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:18:34Z","timestamp":1791494314797,"version":"4.3.4"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,6,17]]},"abstract":"\n Importance<\/jats:title>\n Amiloride has been proposed as an alternative to spironolactone for treating resistant hypertension. However, no randomized clinical trials have compared the efficacy of spironolactone and amiloride in patients with resistant hypertension.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether amiloride is noninferior to spironolactone in reducing home-measured systolic blood pressure (SBP) in patients with resistant hypertension.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Prospective, open-label, blinded end-point randomized clinical trial conducted at 14 sites in South Korea. From November 16, 2020, to February 29, 2024, 118 patients with home SBP of 130 mm Hg or greater after a 4-week run-in period with a fixed-dose triple medication combination (angiotensin receptor blocker, calcium channel blocker, and thiazide) were enrolled.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Patients were randomized in a 1:1 ratio to receive 12.5 mg\/d of spironolactone (n\u2009=\u200960) or 5 mg\/d of amiloride (n\u2009=\u200958). If home SBP remained 130 mm Hg or greater and serum potassium was less than 5.0 mmol\/L after 4 weeks, dosages were increased to 25 mg\/d and 10 mg\/d, respectively.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was the between-group difference in home SBP change at week 12, with a noninferiority margin of \u22124.4 mm Hg for the lower bound of the confidence interval. Secondary end points included achievement rates of home- and office-measured SBP of less than 130 mm Hg.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The median age of the study population was 55 years, with 70% male. There were no differences between groups in demographic characteristics other than use of \u03b1-blockers (8.6% in the amiloride group and 0% in the spironolactone group). The mean baseline home SBPs were 141.5 (SD, 7.9) mm Hg and 142.3 (SD, 8.5) mm Hg in the amiloride and spironolactone groups, respectively. At week 12, mean home SBP measurements were changed from baseline by \u221213.6 (SD, 8.6) mm Hg and \u221214.7 (SD, 11.0) mm Hg in the amiloride and spironolactone groups, respectively (between-group difference in change, \u22120.68 mm Hg; 90% CI, \u22123.50 to 2.14 mm Hg), with amiloride demonstrating noninferiority to spironolactone. Home-measured achievement rates of SBP less than 130 mm Hg in the amiloride and spironolactone groups were 66.1% and 55.2%, respectively, and office-measured achievement rates of SBP less than 130 mm Hg were 57.1% and 60.3%, respectively, with no difference between the 2 groups. One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Amiloride was noninferior to spironolactone in lowering home SBP, suggesting that it could be an effective alternative for treatment of resistant hypertension.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04331691<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2025.5129","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:01:18Z","timestamp":1747220478000},"page":"2073","source":"Crossref","is-referenced-by-count":34,"title":["Spironolactone vs Amiloride for Resistant Hypertension"],"prefix":"10.1001","volume":"333","author":[{"given":"Chan Joo","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hyun","family":"Ihm","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Bucheon St Mary\u2019s Hospital and the Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ho","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Internal Medicine, Severance Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ok","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Cardiology in Internal Medicine, Chungnam National University College of Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Han","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong-Hyeon","family":"Chun","sequence":"additional","affiliation":[{"name":"Division of Cardiology, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea"},{"name":"Now with Division of Cardiology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiWung","family":"Ryu","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Dankook University Hospital, Cheonan, Republic of Korea"},{"name":"Now with Division of Cardiology, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonghoon","family":"Choi","sequence":"additional","affiliation":[{"name":"Now with Division of Cardiology, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Mi","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Wonkwang University Sanbon Hospital, Gunpo, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hyun","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Il","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinho","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wook Bum","family":"Pyun","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Hee","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungha","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"joi250024r1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","article-title":"Prevalence of apparent treatment-resistant hypertension in the United States.","volume":"73","author":"Carey","year":"2019","journal-title":"Hypertension"},{"issue":"1","key":"joi250024r2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40885-023-00255-4","article-title":"Resistant hypertension: consensus document from the Korean Society of Hypertension.","volume":"29","author":"Park","year":"2023","journal-title":"Clin Hypertens"},{"issue":"5","key":"joi250024r3","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association.","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"issue":"2","key":"joi250024r4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients.","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"issue":"13","key":"joi250024r5","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients.","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"issue":"5","key":"joi250024r6","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1161\/HYPERTENSIONAHA.114.03850","article-title":"Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"64","author":"Muntner","year":"2014","journal-title":"Hypertension"},{"issue":"12","key":"joi250024r7","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension, endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"10008","key":"joi250024r8","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"joi250024r9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone.","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"issue":"6","key":"joi250024r10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"joi250024r11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/HJH.0000000000000762","article-title":"Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses.","volume":"34","author":"Roush","year":"2016","journal-title":"J Hypertens"},{"issue":"1","key":"joi250024r12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40885-023-00234-9","article-title":"The 2022 focused update of the 2018 Korean Hypertension Society guidelines for the management of hypertension.","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Hypertens"},{"issue":"9","key":"joi250024r13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019).","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens Res"},{"issue":"33","key":"joi250024r14","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension.","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"6","key":"joi250024r15","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/HYP.0000000000000065","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"1","key":"joi250024r16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants.","volume":"333","author":"World Medical Association","year":"2025","journal-title":"JAMA"},{"issue":"18","key":"joi250024r17","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"Twenty-four-hour blood pressure\u2013lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study.","volume":"139","author":"Kario","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"joi250024r18","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/jch.13367","article-title":"Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: the SHIFT-J study.","volume":"20","author":"Kario","year":"2018","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"joi250024r19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/MBP.0000000000000096","article-title":"Validation of three automatic devices for the self-measurement of blood pressure according to the European Society of Hypertension international protocol revision 2010: the Omron HEM-7130, HEM-7320F, and HEM-7500F.","volume":"20","author":"Takahashi","year":"2015","journal-title":"Blood Press Monit"},{"issue":"4","key":"joi250024r20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41371-021-00536-1","article-title":"Validation of Omron HEM-9200T, a home blood pressure monitoring device for the upper arm, according to the American National Standards Institute\/Association for the Advancement of Medical Instrumentation\/International Organization for Standardization 81060-2:2013 protocol.","volume":"36","author":"Takahashi","year":"2022","journal-title":"J Hum Hypertens"},{"issue":"3","key":"joi250024r21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1345\/aph.1L496","article-title":"Comparison of methods to assess medication adherence and classify nonadherence.","volume":"43","author":"Hansen","year":"2009","journal-title":"Ann Pharmacother"},{"key":"joi250024r22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1472-6904-11-4","article-title":"Use, tolerability and compliance of spironolactone in the treatment of heart failure.","volume":"11","author":"Lachaine","year":"2011","journal-title":"BMC Clin Pharmacol"},{"issue":"4","key":"joi250024r23","doi-asserted-by":"publisher","DOI":"10.1177\/1470320320975893","article-title":"Amiloride: a review.","volume":"21","author":"Sun","year":"2020","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"3","key":"joi250024r24","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1161\/HYPERTENSIONAHA.120.14481","article-title":"Epithelial sodium channel and salt-sensitive hypertension.","volume":"77","author":"Mutchler","year":"2021","journal-title":"Hypertension"},{"issue":"11 pt 1","key":"joi250024r25","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension.","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"issue":"4","key":"joi250024r26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension.","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"issue":"10","key":"joi250024r27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"5","key":"joi250024r28","doi-asserted-by":"publisher","first-page":"R895","DOI":"10.1152\/ajpregu.00099.2018","article-title":"Nicotine and the renin-angiotensin system.","volume":"315","author":"Oakes","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"4","key":"joi250024r29","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1161\/HYPERTENSIONAHA.116.07806","article-title":"Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension.","volume":"68","author":"Dudenbostel","year":"2016","journal-title":"Hypertension"},{"issue":"10208","key":"joi250024r30","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2834040\/jama_lee_2025_oi_250024_1749674944.92066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T11:00:27Z","timestamp":1750158027000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2834040"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":30,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,6,17]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.5129","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}